CD8A and neoplasm: The CD8 Mb PET technology offers a potential method to quantify tumor-infiltrating lymphocytes as proof of mechanism, complimenting tissue biopsy and standard of care imaging if timing can be optimized to account for observation of critical active T cell populations.